Impacto for Smoking, Cessation

Phase-Based Progress Estimates
Smoking, Cessation
Impacto (Mobile App) - Behavioral
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial will test a mobile app called Impacto, which is designed to help Spanish-speakers quit smoking.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Smoking, Cessation

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: Weeks 2, 4, 6, and 8

Week 8
Change in Anxiety Sensitivity
Change in Mood and Anxiety Symptoms
Change in Smoking Rate (# cigarettes per day)
Week 8
Daily Adherence to Use of Impacto Mobile App (Impacto Condition Only)
Week 8
7-Day Point Prevalence Smoking Abstinence
Week 2
User Satisfaction with the Impacto Mobile App (Impacto Condition Only) Condition Only)

Trial Safety

Safety Progress

1 of 3

Other trials for Smoking, Cessation

Trial Design

2 Treatment Groups

Dejar de Fumar Asistente
1 of 2
1 of 2
Active Control
Experimental Treatment

38 Total Participants · 2 Treatment Groups

Primary Treatment: Impacto · No Placebo Group · N/A

Experimental Group · 1 Intervention: Impacto (Mobile App) · Intervention Types: Behavioral
Dejar de Fumar Asistente
ActiveComparator Group · 1 Intervention: Dejar de Fumar Asistente (Mobile App) · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: weeks 2, 4, 6, and 8

Who is running the clinical trial?

University of HoustonLead Sponsor
123 Previous Clinical Trials
39,128 Total Patients Enrolled
3 Trials studying Smoking, Cessation
430 Patients Enrolled for Smoking, Cessation
National Institute on Drug Abuse (NIDA)NIH
2,225 Previous Clinical Trials
5,612,889 Total Patients Enrolled
72 Trials studying Smoking, Cessation
19,588 Patients Enrolled for Smoking, Cessation

Eligibility Criteria

Age 18 - 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 17th, 2021

Last Reviewed: October 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.